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The Clostridium difficile spo0A Gene Is a Persistence and
Transmission Factor
Laura J. Deakin,a Simon Clare,a Robert P. Fagan,b Lisa F. Dawson,c Derek J. Pickard,a Michael R. West,a Brendan W. Wren,c
Neil F. Fairweather,b Gordon Dougan,a and Trevor D. Lawleyd
Microbial Pathogenesis Laboratory, Wellcome Trust Sanger Institute, Hinxton, United Kingdoma; Center for Molecular Microbiology and Infection, Imperial College of
London, London, United Kingdomb; Department of Pathogen Molecular Biology, London School of Hygiene and Tropical Medicine, University of London, London, United
Kingdomc; and Bacterial Pathogenesis Laboratory, Wellcome Trust Sanger Institute, Hinxton, United Kingdomd
Clostridium difficile is a major cause of chronic antibiotic-associated diarrhea and a significant health care-associated pathogen
that forms highly resistant and infectious spores. Spo0A is a highly conserved transcriptional regulator that plays a key role in
initiating sporulation in Bacillus and Clostridium species. Here, we use a murine model to study the role of the C. difficile spo0A
gene during infection and transmission. We demonstrate that C. difficile spo0A mutant derivatives can cause intestinal disease
but are unable to persist within and effectively transmit between mice. Thus, the C. difficile Spo0A protein plays a key role in
persistent infection, including recurrence and host-to-host transmission in mice.
C
lostridium difficile is a Gram-positive, sporogenic, anaerobic
bacterium that is the most common cause of antibiotic-asso-
ciated diarrhea within health care systems of the developed world
(24, 34). Perturbation of the hosts’ indigenous microbiota by
broad-spectrum antibiotic treatment, such as clindamycin, is a
major risk factor for C. difficile colonization, disease, and trans-
mission (4, 10). C. difficile colonization is associated with a spec-
trum of outcomes ranging from asymptomatic carriage, chronic
diarrhea, and pseudomembranous colitis to multiple-organ dys-
function syndrome (6, 17). The first-line antibiotic treatment for
C. difficile disease is vancomycin or metronidazole (39); however,
recurrent disease (relapse with the same strain or reinfection with
a different strain) occurs in !15 to 35% of patients (1). Recur-
rence and transmission are relatively poorly understood aspects of
C. difficile biology that likely underpin its persistence within health
care systems.
During the past decade, distinct genetic clades of C. difficile
have emerged that are responsible for epidemics within North
America and Europe and continue to disseminate globally (18,
19). Among the most notable of these clades is the so-called “hy-
pervirulent” variant of C. difficile, commonly genotyped as PCR
ribotype 027 or North American pulsotype 1, which is associated
with high rates of mortality and disease recurrence, as well as
severe hospital outbreaks (7, 12, 36, 37). In addition, other genetic
variants, such as C. difficile PCR ribotype 012, continue to be en-
demic in health care systems (2).
Sporulation, the production of metabolically dormant en-
dospores from vegetative cells, is a property of several bacterial
groups, including Clostridium and Bacillus (25, 38). In Bacillus,
Spo0A is a key transcriptional regulator that is required in the
early stages of sporulation (23). Orthologues of Spo0A are en-
coded by different members of the genera Clostridium and Bacil-
lus, and genetic inactivation results in a sporulation-null pheno-
type in all species studied to date (9, 25, 28, 35). C. difficile
produces highly infective endospores that are excreted by infected
patients, allowing the oxygen-sensitive pathogen to retain viability
outside the host (22). Spores of C. difficile can also resist com-
monly used disinfectant regimens and, as a result, are able to per-
sist in the environment, generating a potential transmission res-
ervoir that confounds standard infection control measures (5,
11, 20).
C. difficile is unusual among some spore-forming pathogens,
including other clostridia, in being highly transmissible between
humans. In contrast, there is little evidence of person-to-person
transmission of Clostridium botulinum (32), Clostridium tetani
(8), or Bacillus anthracis (30). Thus, transmissibility may be key to
the continued survival and persistence of C. difficile in the human
population, and it suggests that the pathogen is highly adapted to
its niche. Here, we use a murine model of C. difficile infection to
investigate the role of the spo0A gene in distinct PCR ribotypes 027
and 012 during infection and transmission.
MATERIALS AND METHODS
C. difficile strains and culture. All C. difficile strains were grown for 24 to
48 h at 37°C under anaerobic conditions in a MACS MG-500 anaerobic
workstation (Don Whitley Scientific, West Yorkshire, United Kingdom).
C. difficile was routinely cultured in Wilson’s broth with agitation (80
rpm) or on brain heart infusion (BHI) (Sigma, United Kingdom) agar
plates with appropriate antibiotic selection unless otherwise stated. Esch-
erichia coli strains were grown at 37°C using Luria-Bertani (LB) broth or
agar with appropriate antibiotic selection. Table 1 describes the strains
used in this study.
C. difficile was enumerated from fresh feces as previously described
(21). Briefly, samples (100 mg feces/ml phosphate-buffered saline [PBS])
were serially diluted in PBS and plated on CCEY agar (Bioconnections,
Whetherby, United Kingdom) supplemented with 0.1% taurocholate
(Sigma, United Kingdom). This was done within 30 min of excretion. For
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the enumeration of spores, samples were mixed with 100% ethanol (1:1
ratio) for 1 h at room temperature to kill vegetative cells, pelleted, washed
in PBS, and cultured as described above.
Mutagenesis and genetic complementation. ClosTron technology
was used to make targeted mutants in the spo0A gene of C. difficile strains
R20291 (PCR ribotype 027) and 630 (PCR ribotype 012), as previously
described (13, 14). Briefly, the group II Ll.LtrB intron was retargeted to
spo0A by SOE PCR as previously described (13, 14). The retargeted intron,
an antisense insertion between nucleotides 178 and 179, was then cloned
into the HindIII and BsrGI sites of pMTL007 (C. difficile 630) or
pMTL007C-E2 (C. difficile R20291) and transformed into the E. coli con-
jugation donor strain CA434. C. difficile strains 630 and R20291 were
mated with the E. coli donor harboring the retargeted pMTL007 or
pMTL007C-E2, respectively, as previously described (26). Transconju-
gants were selected for in the presence of thiamphenicol (15 "g/ml;
Sigma-Aldrich, Dorset, United Kingdom). For pMTL007, mobilization of
the intron to the spo0A gene of C. difficile 630 was induced using isopro-
pyl-#-D-thiogalactopyranoside (IPTG) as previously described (14).
pMTL007C-E2 is a version of pMTL007 in which the promoter of the
group II intron is modified for a constitutive fdx promoter (13) and as
such does not require IPTG induction to direct intron expression to the
spo0A gene of C. difficile R20291. Potential transconjugants were then
serially diluted onto plates containing lincomycin (15 "g/ml; C. difficile
R20291; Sigma-Aldrich, Dorset, United Kingdom) or erythromycin (5
"g/ml; C. difficile 630; Sigma-Aldrich, Dorset, United Kingdom) to select
for chromosomal insertion of the intron. Replica plating with lincomycin
(15 "g/ml) or erythromycin (5 "g/ml) and thiamphenicol (15 "g/ml) was
performed to select for the restored ermB retrotransposition-activated
marker (RAM) that signals integration into the genome and loss of the
catP gene encoding thiamphenicol resistance carried on the plasmid. Mu-
tants were screened by PCR (see Table S1 in the supplemental material),
sequencing, or Southern blot analysis to confirm the chromosomal inte-
gration of the intron within the desired genes and loss of plasmids
pMTL007 and pMTL007C-E2.
To complement the spo0A mutants, the C. difficile-E. coli shuttle vector
pRPF101 was constructed using the ColE1 replicon from pBlueScript II
SK($) (Agilent Technologies, Cheshire, United Kingdom), catP from
pJIR418 (31), the C. difficile pCD6 replicon (26), and oriT from pJB665
(3). The wild-type C. difficile 630 spo0A gene and upstream promoter
region were amplified using the oligonucleotide pair spo0A_A1F and
spo0A_A2Rb (see Table S1 in the supplemental material), which were
designed to enable cleavage with SalI, and cloned into pRPF101, yielding
pspo0A. Since the amino acid sequences of Spo0A in both C. difficile
R20291 and 630 are identical, only one plasmid was constructed for the
complementation of both strains. pspo0A was initially transformed into E.
coli CA434, followed by conjugation into the spo0A mutant derivatives as
previously described (26), generating strains R20291%spo0A(pspo0A) and
630%spo0A(pspo0A), respectively. Thiamphenicol (15 "g/ml) was used to
select for the pspo0A-containing cells, and cycloserine (250 "g/ml; Bio-
connections, Whetherby, United Kingdom) and cefoxitin (8 "g/ml; Bio-
connections, Whetherby, United Kingdom) were used to counterselect
for E. coli CA434. Plasmid transfer was verified by pspo0A isolation and
restriction analysis (data not shown).
Mouse infections. All experiments were carried out using 5- to
9-week-old specific-pathogen-free mice from colonies maintained at the
Wellcome Trust Sanger Institute. Wild-type mice of C57BL/6 genetic
background were pretreated with drinking water containing clindamycin
(250 mg/liter; Apollo Scientific, Cheshire, United Kingdom) for 7 days.
Clindamycin was then withdrawn for 24 h, and donors were infected via
oral gavage or transmission, as indicated. When infected via oral gavage,
mice received 107 vegetative cells and 105 spores (R20291 and 630 parental
strains) or 107 vegetative cells (R20291%spo0A and 630%spo0A mutant
derivatives). For relapsing infection experiments, mice received drinking
water containing vancomycin hydrochloride (400 mg/liter; Sigma-Al-
drich, Dorset, United Kingdom) for 7 to 10 days. The mice were housed in
sterile cages with ad libitum access to food and water. All procedures and
mouse handling were performed aseptically in a biosafety cabinet to con-
tain spore-mediated transmission.
A clinical scoring system was employed to track the condition of the
mice. Symptoms, including abnormal/hunched gait, piloerection, leth-
argy, and emaciation, were monitored. Moribund mice or mice displaying
overt signs of disease were sacrificed. For pathological analysis, cecum
tissue (0.5-cm tubular sections) was carefully excised, opened, and pro-
cessed for hematoxylin and eosin staining, as previously described (21).
All animal infections were performed in accordance with the United
Kingdom Home Office Animals (Scientific Procedures) Act of 1986.
Competitive-index infections. Wild-type C57BL/6 mice (n & 5) were
infected via oral gavage with 107 CFU in 0.2 ml PBS containing equal
proportions of the C. difficile parental strain and the respective isogenic
spo0A mutant. In order to determine the inoculum dose and ratio of
TABLE 1 Strains and plasmids used in this study
Strain or plasmid Characteristics Source
Strains
E. coli CA434 Conjugation donor 26
C. difficile
Wild-type 630 Virulent and multidrug-resistant PCR ribotype 012, isolated from a patient with
pseudomembranous colitis in Zurich, Switzerland (1985)
29
630 Erythromycin-sensitive derivative of wild-type C. difficile 630 16
R20291 Hypervirulent and epidemic PCR ribotype 027, isolated from a hospital outbreak
in Stoke Mandeville, UK (2004–2005)
33
630%spo0A C. difficile 630%ermB spo0A::ermB This study
R20291%spo0A C. difficile R20291 spo0A::ermB This study
630%spo0A$pspo0A Complemented 630%spo0A mutant This study
R20291%spo0A$pspo0A Complemented R20291%spo0A mutant This study
Plasmids
pMTL007 First-generation ClosTron plasmid with catP marker and intron containing ermB
RAM; intron expression is induced using IPTG.
14
pMTL007C-E2 Second-generation ClosTron plasmid with catP marker and intron containing
ermB RAM; contains a constitutive fdx promoter to direct intron expression
13
pRPF101 E. coli-C. difficile shuttle vector This study
pspo0A pRPF101 containing the 825-bp spo0A coding region (and upstream promoter) This study
C. difficile Persistence and transmission
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parent to spo0A mutant, the inocula were grown on both CCEY plates (as
a nonselective medium) and CCEY plates supplemented with 20 mg/ml
lincomycin (which selects for the ermB gene inserted into the spo0A genes
of both mutant derivatives). Fecal samples were then diluted as described
above and plated on CCEY agar and CCEY agar supplemented with lin-
comycin, and the competitive index (CI) was determined by dividing the
ratio of mutant to parent bacteria using the following formula: CI &
(spo0A mutant/parental strain)output/(spo0A mutant/parental strain)input.
The Mann-Whitney test was applied to the log10 values of the CI ratios to
determine the statistical significance of the results.
Transmission experiments. Wild-type C57BL/6 donor mice (n & 5)
were infected via oral gavage (107 CFU in 0.2 ml PBS). To measure trans-
mission efficiency, naïve wild-type C57BL/6 recipient mice (n & 5) were
pretreated with clindamycin as described above and used in one of four
types of transmission assays as described in Table 2 and Fig. S1 in the
supplemental material. Following transmission, recipient mice were indi-
vidually housed, and the transmission efficiency was determined after 4
days by the isolation of the same strain of C. difficile in the feces that was
used to infect the respective donor mice.
TcdA and TcdB quantification. C. difficile cultures were growth in
Wilson’s broth with shaking for 30 h and pelleted by centrifugation, and
the supernatant was removed for TcdA and TcdB quantification. Total
and spore counts were determined to ensure equal numbers of vegetative
cells in the cultures. For TcdA quantification, microtiter plates were
coated with capture antibody by adding 50 "l/well of a 2-"g/ml solution
of anti-TcdA (tgcBiomics GmbH, Mainz, Germany) in PBS and incubat-
ing overnight at 4°C. The plates were then washed 3 times in 0.05%
Tween20 in PBS (PBS-T) and blocked with 200 "l 1% bovine serum
albumin (BSA) in PBS for 2 h at room temperature. Purified TcdA
(tgcBiomics GmbH, Mainz, Germany) was diluted in 1% BSA-PBS (50
"l/well) and used to construct a standard curve. Culture filtrates (50 "l/
well) were diluted as described above in order to generate readings within
the linear range of the standard curve. Plates were then incubated at room
temperature for 2 h, followed by washing in PBS-T as described above.
The detection antibody (rabbit anti-Clostridium difficile TcdA; Antibod-
ies-Online GmbH, Aachen, Germany) was diluted 1:5,000 in 1% BSA-
PBS, added to the wells (50 "l/well), and incubated for 2 h at room tem-
perature. After washing, polyclonal swine anti-rabbit IgG conjugated to
horseradish peroxidase (HRP) (Dako, Cambridgeshire, United King-
dom) was diluted 1:1,000 in 1% BSA-PBS, added to the wells (50 "l/well),
and incubated for 2 h at room temperature. Finally, the plates were
washed, and 100 "l 3,3=,5,5=-tetramethylbenzidine (TMB) (Sigma-Al-
drich, Dorset, United Kingdom) substrate was added for 30 min at room
temperature in the dark; 50 "l 0.5 M H2SO4 was added to stop the reac-
tion.
TcdB quantification was determined using a TcdB-specific enzyme-
linked immunosorbent assay (ELISA) kit according to the manufacturer’s
instructions (tgcBiomics GmbH, Mainz, Germany). Briefly, microtiter
plates precoated with anti-TcdB capture antibody were coincubated with
either C. difficile culture filtrates or purified TcdB (as described above) and
anti-C. difficile TcdB-HRP and incubated for 1 h at 37°C. The plates were
then washed, and 100 "l TMB substrate was added for 30 min at room
temperature in the dark. The reaction was stopped with 50 "l 0.5 M
H2SO4. The absorbances of all plates were measured at 450 nm on a
FluoStar Omega (BMG Labtech, Bucks, United Kingdom). Data for TcdA
and TcdB are from 3 independent experiments performed in triplicate.
Indirect immunofluorescence of C. difficile vegetative cells and
spores. Cultures were washed in PBS and seeded onto microscope slides.
Briefly, the slides were then fixed in acetone and blocked with 1% BSA in
PBS. The wells were incubated with polyclonal rabbit sera (raised against
pure wild-type C. difficile 630 spores) and polyclonal mouse sera (raised
against 630%spo0A vegetative cells), washed in PBS, and reacted with Cy3-
conjugated goat anti-rabbit IgG and fluorescein isothiocyanate (FITC)-
conjugated goat anti-mouse IgG (each 1:1,000) in a humidified chamber
in the dark. The slides were then mounted in ProLong Gold with DAPI
(4=,6-diamidino-2-phenylindole) (Invitrogen, Paisley, United Kingdom)
and sealed, and immunofluorescence was assessed using an LSM510 Meta
confocal microscope (Carl Zeiss Ltd., Herts, United Kingdom).
Antibodies were generated via subcutaneous delivery of C. difficile
630%spo0A into C57BL/6 mice (for anti-vegetative-cell sera; n & 5) or C.
difficile 630 pure spores into rabbits (for anti-spore sera; n & 2). Briefly,
the animals received 100 "l of an !108-CFU/ml culture in each flank,
followed by a series of boost immunizations and test bleeds. Sera were
collected and stored at 4°C.
RESULTS
C. difficile spo0A is essential for spore formation. We had pre-
viously sequenced and fully annotated the complete genomes of
representative C. difficile ribotypes 027 (strain R20291) (33) and
012 (strain 630) (29). C. difficile R20291 and 630 both produce
!105 spores/ml after 48 h of growth in Wilson’s broth, represent-
ing '1% of the total bacterial cells (Fig. 1A). To evaluate the
impact of spo0A on growth and sporulation, defined insertional
mutations were generated in the spo0A genes of either C. diffi-
cile R20291 or C. difficile 630, yielding mutant derivatives
R20291%spo0A and 630%spo0A, respectively. The vegetative cells
of both R20291%spo0A and 630%spo0A were morphologically in-
distinguishable from the respective parent strains when examined
by light microscopy and displayed similar growth kinetics (data
not shown). Both C. difficile spo0A mutant derivatives failed to
produce any detectable spores or spore-like elements (15, 35), as
determined by anaerobic culturing after ethanol shock (spores are
resistant to ethanol) and indirect immunofluorescence using
spore-specific antisera (Fig. 1).
To demonstrate that the asporogenous phenotype was directly
attributable to the spo0A mutation, we complemented the mu-
tated genes using the plasmid pspo0A harboring the wild-type
spo0A gene under the control of its native promoter. We found
that the complemented spo0A mutants produced spores at levels
comparable to those of the parent (P ( 0.05) and were morpho-
logically indistinguishable (Fig. 1). Collectively, these observa-
tions indicate that the spo0A mutation is nonpolar and that ex-
pression of the spo0A gene is critical for vegetative cells to
differentiate into spores in both C. difficile R20291 and 630.
C. difficile spo0A mutant derivatives cause acute disease in
mice. We previously described a C. difficile infection model in
mice that mimics many aspects of C. difficile disease, persistence,
TABLE 2 Summary of transmission routes
Type of
transmission (1 h) Characteristics
Mingling Donor and recipient mice were able to freely touch
and interact with no restriction in movement;
potential for coprophagy
Contact Donor and recipient mice were separated by a
single porous barrier and were able to touch
each other; no potential for coprophagy
Airborne Donor and recipient mice were separated by a
double porous barrier and were unable to touch
each other; no potential for coprophagy
Environmental Recipient mice were housed in a contaminated
donor cage, which had been left for 24 h under
ambient oxygen conditions. Donor feces were
removed to prevent transmission via
coprophagy
Deakin et al.
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and transmission in humans (20–22). In order to investigate the
role of the spo0A gene during the acute phase of C. difficile infec-
tion (days 2 to 4 postinfection), we pretreated mice with clinda-
mycin and subsequently infected them with C. difficile R20291, C.
difficile 630, or their equivalent spo0A mutant derivatives. Groups
of mice infected orally with C. difficile 630 or 630%spo0A did not
exhibit any overt signs of disease and had a 100% survival rate
(Fig. 2A). In contrast, mice infected with C. difficile R20291 dem-
onstrated notable signs of disease, such as hunched posture and
ruffled fur; however, these clinical symptoms resolved by day 5
postinfection, and all the mice survived. Mice infected with C.
difficile R20291%spo0A also displayed signs of overt disease, but
this was more exaggerated than in R20291-infected mice, with
the mice displaying hunched posture, piloerection, lethargy, de-
hydration, and emaciation. By day 5 postinfection, 80% of
R20291%spo0A-infected mice were considered to be moribund
according to a clinical scoring system and were consequently sac-
rificed. The remaining 20% resolved the disease and survived.
In order to identify any increased pathology associated with
R20291%spo0A infection, we performed histologic analyses on the
ceca of mice infected with C. difficile R20291 or R20291%spo0A at
day 2 postinfection (Fig. 2B). At this time point, the mice shed
equivalent levels (!108 CFU/gram fresh feces) of vegetative C.
difficile R20291 or R20291%spo0A. Mice infected with C. difficile
R20291 also shed spores (!106 CFU/gram fresh feces), in contrast
to R20291%spo0A-infected mice, which did not shed spores. Un-
infected clindamycin control mice did not exhibit any pathology.
Conversely, at day 2 postinfection, mucosal damage was evident in
R20291- and R20291%spo0A-infected mice, which included
edema and immune cell infiltrate within the cecal mucosa. These
observations, however, were much more notable in mice infected
with R20291%spo0A, which exhibited more pronounced edema,
epithelial surface damage, and acute infiltration. Putative pseu-
domembranes were also visible on the epithelial surface in
R20291%spo0A-infected mice.
FIG 1 Genetic and phenotypic characterization of C. difficile 630 and R20291
spo0A mutants. (A) C. difficile cultures were grown in Wilson’s broth for 48 h
under anaerobic conditions, and then total cell and spore counts were deter-
mined. Genetic complementation of the spo0A mutation restored spore for-
mation to levels statistically comparable to those of the parental strains (P (
0.05), according to the Student t test. The dashed horizontal line indicates the
detection limit. The error bars indicate standard deviations. (B) Representative
indirect-immunofluorescence images of C. difficile cultures stained with veg-
etative-cell-specific (green) and spore-specific (red) polyclonal antibodies and
visualized with FITC-conjugated and Cy3-conjugated secondary antibodies,
respectively. Scale bar & 5 "m.
FIG 2 C. difficile spo0A mutants produce elevated levels of TcdA and TcdB and
exhibit increased virulence in mice. (A) Kaplan-Meier survival curve of mice
infected with C. difficile 630, R20291, 630%spo0A, or R20291%spo0A. (B) Rep-
resentative images demonstrating epithelial cell damage in hematoxylin- and
eosin-stained cecal sections of mice infected with C. difficile R20291 or
R20291%spo0A. Magnification, )20. (C) Sandwich ELISA indicating the rel-
ative levels of TcdA and TcdB produced by C. difficile R20291 or
R20291%spo0A after 30 h of growth in Wilson’s broth under anaerobic condi-
tions. Data are from 3 independent experiments performed in triplicate. The
error bars indicate standard deviations.
C. difficile Persistence and transmission
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The increased virulence exhibited by C. difficile R20291%spo0A
was not anticipated. We hypothesized that these observations
might be related to increased toxin production. We therefore
compared the levels of the major toxins TcdA and TcdB from
broth grown cultures of wild-type C. difficile R20291 and
R20291%spo0A using highly sensitive anti-TcdA- and anti-TcdB-
specific ELISAs. Low-levels of TcdA and TcdB were detected
during mid-exponential-phase growth in both R20291 and
R20291%spo0A (data not shown). However, during stationary
growth (30 h), significantly higher levels both of TcdA (P &
0.0006) and TcdB (P & 0.0005) were detected in C. difficile
R20291%spo0A than in R20291 cultures (Fig. 2C). Complementa-
tion of the spo0A gene in R20291%spo0A reduced the levels of
toxins produced, although both TcdA and TcdB were still slightly
elevated compared to that produced by wild-type C. difficile
R20291 (P & '0.05).
Therefore, we demonstrated that R20291 and R20291%spo0A
are virulent in mice and that exaggerated virulence by
R20291%spo0A during the acute phase of infection is associated
with increased TcdA and TcdB production.
The C. difficile spo0A gene is required for persistent, relaps-
ing infection in mice. We previously demonstrated that C. difficile
isolated from infected hospital patients can asymptomatically per-
sist in mice for several months (21). Therefore, we next assessed
the contribution of the C. difficile spo0A gene to colonization and
persistent infection. To assess this phenotype, CI experiments
were performed in which groups of mice were infected with a
mixture of equal numbers of parental strain C. difficile and the
respective %spo0A mutant, enabling direct fitness comparisons in
vivo. In the R20291 background, the %spo0A mutant was recov-
ered at a significantly reduced level compared to wild-type R20291
(Fig. 3A). We observed that genetic disruption of spo0A resulted in
reduced fitness by day 2 postinfection and continued to day 15
postinfection. Although C. difficile 630 does not cause a long-term
persistent infection in our murine model, we found that the C.
difficile 630%spo0A mutant was reproducibly cleared !6 days ear-
lier than its parental strain (data not shown). Additionally, the
difference in relative fitness for the 630%spo0A mutant was statis-
tically significant by day 5 postinfection (Fig. 3B). These results
indicate that the spo0A gene of C. difficile contributes to intestinal
colonization and persistent infection in mice.
Recurrent infection after cessation of antibiotic therapy is a
hallmark feature of C. difficile persistence. Given that C. difficile
spo0A may affect persistence, we were interested in whether Spo0A
also influences relapsing infection. To test this, mice infected with
R20291, R20291%spo0A, C. difficile 630, or 630%spo0A were
treated with a 7-day course of oral vancomycin. During this pe-
riod, the cages were regularly changed to reduce the potential for
environmental transmission. We found that vancomycin therapy
rapidly decreased the levels of fecal shedding of C. difficile to below
the detection limit in all infected groups of mice (Fig. 4A and B), as
expected, since these strains are sensitive to vancomycin. How-
ever, 3 days after vancomycin withdrawal, the mice infected with
parental C. difficile R20291 or C. difficile 630 exhibited recurrent
infection with the same isolate (i.e., relapse). With C. difficile 630,
this relapsing phenotype was observed after the first two courses of
vancomycin; however, after a third treatment, the relapse did not
occur (Fig. 4B). In contrast, C. difficile R20291-infected mice
consistently relapsed on cessation of treatment for up to 100 days
(Fig. 4A). Significantly, mice infected with either C. difficile
R20291%spo0A or 630%spo0A cleared the infection during the first
FIG 3 C. difficile spo0A mediates intestinal persistence in mice. Shown are the
CI time courses of C. difficile R20291 and R20291%spo0A (A) and 630 and
630%spo0A (B). Individual CI values are illustrated as open circles, and the
horizontal bars represent the geometric means. The second through fourth (A)
and third and fourth (B) spo0A mutants are attenuated, as determined by the
Mann-Whitney test.
FIG 4 The C. difficile spo0A gene is required for relapsing disease in mice. (A
and B) Representative fecal shedding profiles from mice (n & 5 per group)
infected with C. difficile 630, R20291, 630%spo0A, or R20291%spo0A. The mice
were pretreated with clindamycin (clin) (represented as a gray line) for 7 days
prior to infection via oral gavage. Following infection, the mice received a
series of 7- to 10-day courses of vancomycin (van) (represented as green lines)
during which fecal shedding of C. difficile decreased to below the detection
limit of the assay in all groups of mice. The dashed horizontal lines indicate the
detection limit.
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course of vancomycin and did not demonstrate relapse at any
point during the 100-day monitoring period (Fig. 4A and B).
We hypothesized that recurrence in R20291- and 630-infected
mice could be the result of either persistence of the bacterium
within the host during vancomycin therapy or recolonization
from environmental spores. To address this, mice infected with C.
difficile R20291 or C. difficile 630 were treated with a 5-day course
of vancomycin, after which the entire intestinal tract (small and
large intestine and cecum) was removed and cultured for C. diffi-
cile. We consistently failed to detect any C. difficile in the intestinal
tracts of mice receiving vancomycin therapy (data not shown).
However, we could readily culture C. difficile from mouse chow,
cage shavings, and bedding, as well as the fur, mouth, and feet of
mice receiving vancomycin treatment, even though cages were
changed during the vancomycin treatment. Spores were detected
in all locations, indicating that Spo0A acts as a persistence factor,
enabling C. difficile to remain in the environment generating an
infection reservoir on cessation of antibiotic therapy.
C. difficile spo0A is required for efficient host-to-host trans-
mission. We previously used the murine infection model to dem-
onstrate host-to-host transmission and the highly transmissible
nature of various C. difficile ribotypes (20–22). Here, we used this
model to investigate the role of the C. difficile spo0A gene in host
transmission via distinct transmission routes (Table 2; see Fig. S1
in the supplemental material). During transmission experiments,
the donor mice shed equivalent levels (!108 CFU/gram fresh fe-
ces) of vegetative C. difficile R20291, 630, or their respective spo0A
mutant derivatives (Fig. 5A). Mice infected with C. difficile R20291
or C. difficile 630 also shed spores (!106 CFU/gram fresh feces), in
contrast to mice infected with the spo0A mutants, where spores
were undetectable (Fig. 5A).
Mingling donor mice that were shedding high levels of C. dif-
ficile R20291 or 630 with naïve recipient mice for 1 h (in cages
without bedding) resulted in 100% transmission (Fig. 5B) (n & 10
for each strain). In contrast, mingling donors excreting C. difficile
R20291%spo0A or 630%spo0A with naïve recipient mice resulted
in only 40% or 20% transmission efficiency, respectively. In these
experiments, coprophagy was regularly observed, and this behav-
ior likely promotes C. difficile transmission. To further define the
transmission route, we placed a porous wall between donor and
recipient mice so that the mice could come into contact but
coprophagy was blocked. During these experiments C. difficile
R20291 and 630 were still transmitted at 100% efficiency, whereas
the %spo0A derivatives failed to transmit at a detectable level (Fig.
5B, contact transmission). Next, we tested transmission between
donor and recipient mice that were separated by a double porous
wall that prevented coprophagy and direct contact but would still
allow airborne transmission. In these experiments, C. difficile
R20291 and 630 were transmitted at 60% efficiency, whereas the
respective %spo0A derivatives failed to transmit (Fig. 5B, airborne
transmission). Thus, Spo0A plays a key role in the transmission of
C. difficile between hosts sharing a contained environment but
with no direct contact.
Environmental C. difficile spores are proposed to be a signifi-
cant transmission reservoir (20, 27). To mimic this situation, we
contaminated cages (without bedding) by placing donor mice
shedding C. difficile in cages for 1 h and then removed the feces
and allowed the cages to stand overnight (!16 h) in a sterile en-
vironment so that only the aerobic-resistant spores survived. Ex-
posure of naïve recipient mice to the environment contaminated
with C. difficile R20291 or 630 spores resulted in 100% transmis-
sion to naïve recipient mice. In contrast, none of the naïve recip-
ient mice exposed to C. difficile R20291%spo0A- or 630%spo0A-
contaminated cages became colonized (Fig. 5B).
DISCUSSION
The availability of a murine infection model opens the way to
study the genetic basis of C. difficile disease, relapse, persistence,
and transmission. Here, we demonstrated for the first time that
the spo0A gene of clinically relevant genetic variants of C. difficile is
essential for persistent infection and efficient host-to-host trans-
mission. Importantly, we also showed that a functional spo0A gene
is required for relapsing infection after vancomycin therapy, and
we further illustrated that the local environment (i.e., cage, food,
mouse fur, etc.) may serve as a reservoir of C. difficile. Despite
FIG 5 Host-to-host transmission of C. difficile is mediated by spo0A. (A)
Average fecal shedding of C. difficile by mice (n & 5 per group) at 5 days
postinfection. The dashed horizontal line indicates the detection limit. The
error bars indicate standard deviations. (B) Transmission efficiencies of C.
difficile 630, R20291, 630%spo0A, and R20291%spo0A, demonstrating the per-
centages of naïve recipient mice that acquired infection following exposure to
infected donor mice via mingling, contact, airborne, or environmental trans-
mission. The efficiency of transmission was determined as described in Mate-
rials and Methods.
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multiple attempts, we could not culture C. difficile from the intes-
tinal tracts of challenged mice during vancomycin treatment, in-
dicating that maintenance of C. difficile within the intestinal tract
was not a likely cause of relapse, although we cannot rule out the
possibility that C. difficile persisted at very low levels or in a non-
culturable form. We could, however, readily culture C. difficile
from inside the cage during treatment. Given the highly transmis-
sible nature of environmental spores, it is possible that relapsing
infection was in fact reinfection with the same strain that contam-
inated the local environment before antibiotic treatment and per-
sisted until after antibiotic therapy ended. The inability of C. dif-
ficile spo0A mutants to cause relapsing infection and form spores is
consistent with this model. Indeed, antibiotic treatment of mice
perturbs the intestinal microbiota and makes them extremely sus-
ceptible to C. difficile infection via environmental spores (21).
As expected, genetic inactivation of spo0A resulted in an as-
porogenous phenotype in C. difficile R20291 (ribotype 027) and
630 (ribotype 012) (35). In addition to not being able to form
spores, we demonstrated that C. difficile spo0A mutants produced
elevated levels of the toxins TcdA and TcdB in vitro compared to
the respective wild-type parental strains. Therefore, Spo0A may
negatively regulate toxin production, which was associated with
increased virulence for mice for the C. difficile 027 variant. This
finding was in contrast to the observations of Underwood et al.
(35), which indicated that a C. difficile 630 spo0A mutant pro-
duced '10% of the parental levels of TcdA (35). This discrepancy
may reflect the different methods used to quantify toxin levels. In
the well-characterized model organism Bacillus subtilis, Spo0A
regulates processes other than spore formation, such as efflux
pumps and metabolism (23). Consequently, it is possible that, in
addition to spore formation, there are other functions controlled
by Spo0A that may play a role in persistence and transmission.
Future experiments that define the C. difficile Spo0A regulon at the
transcriptional and proteomic levels should identify persistence
and transmission factors controlled by Spo0A in C. difficile.
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